| Management target | Revenue FY30 |
|---|
| Revenue growth | 23% YoY decline driven by shipment phasing and CDMO destocking. |
|---|---|
| Margins | EBITDA margins severely compressed to 2.2% due to low revenue base. |
| Order book | Significant commercial restocking orders secured for Q4 FY27 and FY28. |
| Demand visibility | Strong RFQ pipeline in late-stage molecules and ADC payloads. |
| Management confidence | Balanced; acknowledging Q1 as a historic low while projecting H2 recovery. |
Growth
Pharma CDMO revenue plunged 38.7% YoY due to destocking, partially offset by 2.5x growth in the Sapala subsidiary.
Outlook
Management expects sequential improvement in Q2 and a return to YoY growth starting in H2 FY27.
Risks
Heavy negative operating leverage at Enzene Biosciences and persistent biotech funding headwinds impact near-term profitability.
Last quarter's promises, checked
Delivered
- Guided Q4/FY26 in line with guidance → delivered FY26 revenue 22.68B (= BEAT)
- Guided FY26 Gross Margin supported by mix → delivered 70.8% (= BEAT)
- Guided FY26 Capex at 2.15B → delivered 2.15B (= BEAT)
Partly delivered
- Guided 10 Phase 3 programs → delivered 10 programs but with biotech delays (= PARTIAL)
Missed
- Guided H2 FY27 growth → delivered Q1 FY27 23% revenue decline (= MISS)
- Guided API+ stability → delivered Q1 FY27 shipment phasing/delays (= MISS)
- Guided EBITDA margin benchmark 30% → delivered 2.2% in Q1 FY27 (= MISS)
Earnings Call Transcript filed with NSE, NSE: COHANCE. Summary written with AI assistance from the document.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹459.25
- Market cap
- ₹17,571 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 165.4×Sector 50.4×
- Promoter holding
- 57.49%+0.00% QoQ
- FII holding
- 6.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Business Update
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Cohance Lifesciences Merger & Restructuring Worth ₹95 Cr
Cohance Lifesciences invested USD 10 million (₹95 Crore) into its subsidiary NJ Bio, Inc. to subscribe for new Compulsorily Convertible Preferred Stock.
- Value
- ₹95.00 Cr
Cohance Lifesciences Annual General Meeting
Cohance Lifesciences Limited conducted its 8th Annual General Meeting on 17 September 2026. All resolutions proposed in the notice were passed by the requisite majority.
Cohance Lifesciences Business Update
Cohance Lifesciences completed a USFDA inspection of its Shamshabad formulation plant, receiving a Form 483 with four observations. The company is initiating corrective measures.
Cohance Lifesciences Acquisition Worth ₹169.2 Cr
Cohance Lifesciences announced a $18 million investment across two subsidiaries, NJ Bio and Aruka Bio, to strengthen its ADC strategy and commercial integration.
- Value
- ₹169.2 Cr
Cohance Lifesciences Investor Presentation: Key Takeaways
Cohance reported a weak Q1FY27 with revenue at INR 4,223 Mn (-23.1% YoY) and adjusted EBITDA at INR 92 Mn (2.2% margin) due to phasing.